Bullish Case: Known: NVAX around 8.9 with backwardated IV and elevated near-term calls. Inferred: credible partnerships or strong Q2 results could push NVAX above 10 toward 11–12 by late summer. Uncertain: hantavirus headlines may fade; price path could stall. The NVAX market surface suggests upside is priced; mean-reversion supports a test of 10–12 if catalysts occur.

Bearish Case: Known: NVAX around 8.9; Term structure backwardation signals near-term risk. Inferred: absent catalysts, downside to 7–8 in 1–3 months plausible. Uncertain: a surprise deal or positive data may avert; If headlines fade, price test 6–7 later; Bearish scenario aligns with prior bearish calls and mean-reversion.

Potential Outcomes:

1. Buyout/partnership lifts NVAX to ≥ $10 by Q3 2026 — 20%
2. Strong Q2 results/regulatory progress lifts to $10–$12 — 25%
3. Range-bound drift between $8.0–$9.5 for 2–4 months — 30%
4. Downside tail to 7–8 within 1–2 months — 15%
5. Regulatory setback/news reduces price to 6–7 — 10%

May 20, 2026